Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CSPC Pharmaceutical Group's Enterprise Value is $9,253 Mil.
CSPC Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $593 Mil. Therefore, CSPC Pharmaceutical Group's EV-to-EBIT ratio for today is 15.61.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
CSPC Pharmaceutical Group (OTCPK:CSPCY) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
CSPC Pharmaceutical Group's EV-to-EBIT for today is
CSPC Pharmaceutical Group's current Enterprise Value is $9,253 Mil.
CSPC Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $593 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
CSPC Pharmaceutical Group's EV-to-EBITDA for today is:
CSPC Pharmaceutical Group's current Enterprise Value is $9,253 Mil.
CSPC Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $793 Mil.
CSPC Pharmaceutical Group's current Enterprise Value is $9,253 Mil.
CSPC Pharmaceutical Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,607 Mil.
CSPC Pharmaceutical Group's current Enterprise Value is $9,253 Mil.
CSPC Pharmaceutical Group's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.
CSPC Pharmaceutical Group's current Enterprise Value is $9,253 Mil.
CSPC Pharmaceutical Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSPC Pharmaceutical Group Enterprise Value Related Terms
CSPC Pharmaceutical Group Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSPCY vs LLY, JNJ, ABBV: Enterprise Value Comparison
For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSPC Pharmaceutical Group Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's Enterprise Value distribution charts can be found below:
* The bar in red indicates where CSPC Pharmaceutical Group's Enterprise Value falls into.
CSPC Pharmaceutical Group Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
CSPC Pharmaceutical Group's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSPC Pharmaceutical Group (CSPCY) has a Enterprise Value of $9,253 Mil as of Jun. 30, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on CSPC Pharmaceutical Group and its competitors.
Is CSPC Pharmaceutical Group's Enterprise Value too high?
CSPC Pharmaceutical Group's current Enterprise Value is $9,253 Mil. Overall, CSPC Pharmaceutical Group has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's Enterprise Value compare to LLY and JNJ?
CSPC Pharmaceutical Group's Enterprise Value of $9,253 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on CSPC Pharmaceutical Group and its competitors. CSPC Pharmaceutical Group's current Enterprise Value is $9,253 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group (CSPCY) is currently considered Fairly Valued. The stock's GF Value™ is $3.37, compared to a current price of $3.58 — trading 6.4% above its estimated fair value. The current Enterprise Value is $9,253 Mil. CSPC Pharmaceutical Group's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For CSPC Pharmaceutical Group (CSPCY), the current Enterprise Value is $9,253 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSPC Pharmaceutical Group (CSPCY) Overvalued in 2026?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued.
The current stock price of $3.58 is trading 6.4% above its estimated GF Value™ of $3.37.
GuruFocus considers CSPC Pharmaceutical Group to be Fairly Valued.
Key valuation signals for CSPCY:
Enterprise Value: $9,253 Mil
GF Value™: $3.37 vs. price of $3.58 (6.4% above fair value)
No single metric tells the full story. See the CSPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
76GF Score
Get the complete analysis for CSPCY
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSPCY has been successfully added to your 
